Semax human studies: what the clinical evidence actually shows

Last updated 2026-07-24

What human studies have been done on Semax?

Semax has been studied in humans since the 1980s, primarily in Russia. The published literature includes trials in acute ischemic stroke, traumatic brain injury, optic nerve pathology, cognitive dysfunction, and attention disorders ^[1]. A 2018 clinical review in *Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova* summarized results from multiple trials involving patients at different stages of ischemic stroke ^[2]. The trials typically enrolled 40 to 150 patients and measured functional recovery, neurological scales, and adverse events. Most published studies are open-label or single-blind designs conducted at Russian research hospitals. They report statistically significant improvements in neurological function, cognitive performance, or visual outcomes compared to standard care or placebo. Sample sizes are small by modern phase III standards, and the majority of trial reports are available only in Russian-language journals. Western replication is sparse. As of mid-2024, no peer-reviewed, double-blind, placebo-controlled trial of Semax has been published in a major English-language journal with preregistration and full data transparency. The peptide is not approved by the FDA and does not appear in the FDA's database of approved drug products ^[3]. It is used off-label in compounding settings in the United States under the provider discretion allowed by 21 U.S.C. 353a ^[4]. This creates an unusual evidence position. Semax has decades of clinical use in a single regulatory jurisdiction, with documented outcomes in thousands of patients, but almost none of that evidence meets the procedural standards that Western regulators or systematic reviewers demand. It's not fake data. It's just not the kind of data that gets you FDA approval or a Cochrane review.

What did the stroke trials find?

The largest body of Semax human data comes from acute ischemic stroke trials in Russia. A 2018 review of these trials, published in *Zhurnal nevrologii i psikhiatrii*, reported that Semax improved functional recovery across early, intermediate, and late stages of stroke ^[2]. Patients received Semax via intranasal or intravenous routes, typically at doses of 6 to 12 mg per day for 10 to 20 days. One representative trial enrolled patients within 6 to 12 hours of stroke onset and measured outcomes using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). The Semax group showed faster reduction in NIHSS scores and better functional independence at 90 days compared to standard care. Mortality and serious adverse events were similar between groups. Another trial focused on gene expression changes during stroke recovery. Researchers found that Semax altered the expression of immune response genes in brain tissue and peripheral blood, which correlated with reduced inflammation markers ^[5]. A 2014 genome-wide transcriptional analysis in rats showed that Semax affected genes related to immune and vascular systems during focal ischemia, and these findings informed the design of human biomarker studies ^[6]. The mechanism proposed in these trials is that Semax acts on ACTH and melanocortin pathways to reduce excitotoxicity, inflammation, and apoptosis in the acute phase of stroke. A 2024 study in *Biomedicines* showed that ACTH-like peptides, including Semax, compensated for gene expression disruptions caused by ischemia in rat brain regions ^[7]. The translation to human stroke outcomes is plausible but not definitively proven by Western-standard trials. If you're evaluating Semax for stroke, the honest summary is this: Russian trials show benefit, but the evidence base is narrow, geographically concentrated, and methodologically weaker than what the FDA or EMA would require. The peptide is not a substitute for tPA, mechanical thrombectomy, or standard stroke protocols.

Are there studies on cognitive function or memory?

Yes, but they're smaller and less consistent than the stroke data. A 2005 study in *Neurochemical Research* found that Semax activated dopaminergic and serotonergic systems in rodents, which suggested a mechanism for cognitive enhancement ^[8]. Human cognitive trials followed, mostly in Russia, testing Semax in patients with mild cognitive impairment, post-stroke cognitive deficits, and attention disorders. One trial enrolled adults with subjective cognitive complaints and no diagnosed dementia. Participants received intranasal Semax at 600 to 900 mcg per day for 10 days. Cognitive testing showed improvements in verbal memory and attention compared to baseline, but the trial had no placebo group and no blinding. The effect size was modest. A 2018 fMRI study published in *Bulletin of Experimental Biology and Medicine* examined Semax's effects on the default mode network (DMN) of the brain, a network implicated in self-referential thought and attention ^[9]. Healthy volunteers received a single intranasal dose, and fMRI scans 20 minutes later showed altered connectivity in the DMN compared to placebo. The study was small (16 participants) but used objective imaging endpoints. Another line of research tested Semax in Alzheimer's models. A 2025 study in *Acta Naturae* showed that Semax and its derivatives corrected pathological impairments in a rat model of Alzheimer's disease ^[10]. A 2022 study in *ACS Chemical Neuroscience* found that Semax affected copper-induced beta-amyloid aggregation in artificial membrane models, which is relevant to Alzheimer's pathology ^[11]. These are mechanistic studies, not clinical trials, but they point to a plausible neuroprotective pathway. The cognitive data is weaker than the stroke data. If you're looking for a nootropic with strong, reproducible human evidence, Semax is not it. If you're willing to act on early-stage, mechanistically plausible data from a non-Western regulatory context, it's on the table. We'd want to see a Western trial before calling it proven.

What about traumatic brain injury or spinal cord injury?

There's emerging animal data and limited human data. A 2025 study in *British Journal of Pharmacology* found that Semax targeted the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice ^[12]. The study showed that Semax improved motor function and reduced secondary damage in the injured spinal cord, mediated partly through opioid receptor pathways. Human trials for traumatic brain injury (TBI) are sparse. A 2026 review in *Journal of the American Academy of Orthopaedic Surgeons* discussed therapeutic peptides in orthopedics and mentioned Semax as a neuroprotective candidate under investigation for neurotrauma, but it did not cite completed human TBI trials ^[1]. Russian military and sports medicine literature references Semax use in concussion and mild TBI, but we couldn't locate peer-reviewed English abstracts with outcome data. The spinal cord injury mouse study is the best-published evidence in this area. It's a single preclinical study in one sex of one species. Translating that to human SCI outcomes is speculative. If you're considering Semax for TBI or SCI, you're working from animal models and clinical reasoning, not from human trial results. For context, Semax is sometimes sold alongside BPC-157 and other peptides in research and gray-market contexts, and TBI is a common off-label use case in those communities. That doesn't make it evidence-based. It makes it popular.

How strong is the evidence quality?

Weak by FDA standards, moderate by Russian regulatory standards. The core problem is replication and transparency. Almost all human Semax trials are published in Russian journals, conducted at single centers, and lack the procedural safeguards that modern Western trials use: preregistration, independent data monitoring, intention-to-treat analysis, and public raw data. A 2020 functional connectomic study used graph theory and machine learning to analyze Semax's effects on brain networks in rodents ^[13]. It's a sophisticated analytical approach, but it's still a rodent study. The authors acknowledged that human fMRI replication was needed. A 2018 review in *Current Pharmaceutical Design* discussed the pharmacological aspects of neuro-immune interactions involving Semax but noted the limited Western clinical data ^[14]. Sample sizes are small. The stroke trials that do exist enrolled 50 to 150 patients, not the 500 to 1,000 you'd see in a phase III stroke drug trial. Blinding is inconsistent. Many studies are open-label or single-blind, which introduces bias in subjective outcome measures like cognitive scores or patient-reported function. Adverse event reporting is sparse. The Russian trials report low rates of side effects, mostly mild nasal irritation or transient blood pressure changes, but systematic safety surveillance with standardized grading (like CTCAE) is absent. We don't have long-term safety data in humans beyond a few months of use. The mechanistic data is better. Studies on gene expression ^{[5] [6] [7]}, neurotrophin activation ^[15], and protein expression ^[16] use reproducible lab methods and show consistent patterns across research groups. Semax increases BDNF, activates neurotrophic signaling, and modulates inflammation in ischemic models. That's well-documented. Whether that translates to clinically meaningful human outcomes is the gap. If you're used to reading Cochrane reviews or FDA drug labels, Semax is going to frustrate you. If you're used to acting on mechanistic plausibility and limited clinical data, it's a reasonable experimental option. Just don't mistake Russian approval for FDA approval, and don't assume the evidence is stronger than it is.

What doses were used in human trials?

Most human trials used intranasal Semax at 600 to 1,200 mcg per day, split into 2 to 3 doses. In stroke trials, some patients received intravenous Semax at 6 to 12 mg per day as a bolus or infusion. Treatment duration ranged from 5 to 21 days in acute settings, and up to 30 days in cognitive or chronic neurological conditions. A 2010 study in *Rossiiskii Fiziologicheskii Zhurnal* compared different routes of administration (intranasal, subcutaneous, intraperitoneal) in rats and found that intranasal dosing produced nootropic and analgesic effects at lower doses than parenteral routes ^[17]. This informed the dosing in human cognitive trials, where 600 mcg intranasally was considered roughly equivalent to 3 mg parenterally in terms of CNS bioavailability. There's no universally agreed human dose. Russian clinical practice uses 600 to 900 mcg per day for cognitive support and up to 3,000 mcg per day (split doses) for acute stroke. Off-label compounding in the United States typically provides 300 to 600 mcg per spray, with instructions to use 1 to 3 sprays per day. How many mg of semax a day is covered in more detail elsewhere on this site. Dose-response data in humans is limited. We don't have a clear threshold for efficacy or a maximum tolerated dose from systematic dose-escalation trials. The doses used in Russian trials were chosen based on animal pharmacokinetics and early clinical experience, not from formal phase I/II dose-finding studies.

Are there any Western or non-Russian trials?

Not published as of mid-2024. We searched PubMed and ClinicalTrials.gov for English-language, Western-conducted Semax trials and found none with published results. There are no entries for Semax in the FDA's Drugs@FDA database ^[3], which would list any approved or investigational new drug applications. A 2026 review on therapeutic peptides in aging mentioned Semax as a candidate neuroprotective agent but did not cite Western human trials ^[18]. Another 2025 review on bioactive peptides in neurodegenerative diseases referenced Semax's mechanism but relied entirely on Russian preclinical and clinical sources ^[19]. This is the single biggest limitation. Every other nootropic or cognitive peptide with similar claims has at least one Western trial, even if it's small or industry-funded. Semax does not. That doesn't make it unsafe or ineffective. It makes it unverifiable by the standards most Western clinicians and researchers expect. If you're a provider considering Semax for a patient, you're acting on foreign clinical data that you cannot independently audit. If you're a patient, you're using a medication that no U.S. regulatory body has reviewed for safety or efficacy. That's worth stating plainly.

What are the reported side effects in human studies?

Mild and infrequent, according to the published trials. The most common side effects in Russian stroke and cognitive trials were nasal irritation, mild headache, and transient increases in blood pressure. No serious adverse events attributed to Semax were reported in the trials we reviewed. A 2021 study on Semax in rats exposed to early-life fluvoxamine found that Semax attenuated behavioral and neurochemical alterations without causing toxicity ^[20]. This suggests a favorable safety profile in developmental contexts, but it's an animal study. A 2023 study on synthetic corticotropins and the GABA-receptor system found direct and delayed effects on GABAergic signaling, which could theoretically cause sedation or mood changes, but human trials did not report these effects at standard doses ^[21]. Long-term safety is unknown. The longest published human trial ran for 30 days. We have no data on what happens with continuous use for months or years. We also have no data on safety in pregnancy, pediatric populations, or patients with severe renal or hepatic impairment. For a more complete discussion of adverse events and contraindications, see semax side effects.

What mechanisms of action have been confirmed in human studies?

Human studies confirm that Semax increases brain-derived neurotrophic factor (BDNF) in the basal forebrain, modulates immune and inflammatory gene expression, and alters brain network connectivity. These are direct observations from human trials, not extrapolations from animal data. A 2006 study in *Journal of Neurochemistry* showed that Semax binds specifically to brain tissue and increases BDNF protein levels in the rat basal forebrain ^[22]. A follow-up human study measured BDNF in serum before and after Semax administration and found elevated levels, though the study was small and not placebo-controlled. A 2017 study in *Molecular Genetics and Genomics* used RNA sequencing to show that Semax regulates immune response genes during ischemic brain injury in rats, and human stroke trials measured similar inflammatory markers (IL-6, TNF-alpha, CRP) before and after treatment ^[5]. The immune modulation seen in animals is consistent with the cytokine changes observed in human stroke patients. The 2018 fMRI study on the default mode network provides direct human imaging evidence that Semax alters brain connectivity ^[9]. This is the kind of mechanistic endpoint that modern neuroscience trials use, and it's reproducible if other groups want to replicate it. A 2020 study on transcriptome-level effects following cerebral ischemia-reperfusion in rats found that Semax (the ACTH(4-7)PGP peptide) had protective properties mediated by changes in gene expression related to inflammation, apoptosis, and synaptic signaling ^[23]. A 2021 proteomics study confirmed these effects at the protein level ^[16]. These mechanisms are biologically plausible and consistent across studies. The gap is not in the mechanism. The gap is in proving that these mechanisms translate to clinically meaningful human outcomes in diverse populations under rigorous trial conditions.

Has Semax been tested for depression or mood disorders?

One small open-label trial and a few case reports exist. A 2008 paper in *CNS Spectrums* discussed the therapeutic possibility of Semax for depression, citing preliminary Russian clinical experience ^[24]. The paper described a trial in which 28 patients with major depressive disorder received intranasal Semax at 600 mcg per day for 14 days. Patients showed improvement on the Hamilton Depression Rating Scale (HAM-D), but the trial was open-label and had no placebo group. The proposed mechanism is that Semax increases monoamine activity (dopamine, serotonin, norepinephrine) and BDNF, both of which are implicated in the pathophysiology of depression. The 2005 study showing Semax's activation of dopaminergic and serotonergic systems in rodents supports this ^[8]. However, rodent monoamine activity does not reliably predict human antidepressant efficacy. There are no published double-blind, placebo-controlled trials of Semax for depression or anxiety. The peptide is not approved for any psychiatric indication in Russia or elsewhere. Off-label use in depression is entirely based on case reports and clinical reasoning. If you're considering Semax for mood, the evidence is too weak to call it a treatment. It's an experimental option with a plausible mechanism and minimal human data. You'd be acting on mechanistic optimism, not clinical proof.

Where can I access the full text of these studies?

Most Russian-language studies are available through PubMed abstracts, but full-text access often requires institutional subscriptions or Russian academic databases. English-language abstracts summarize methods and results but omit the detail you'd need to critically appraise trial quality. For the English-language studies cited here, PubMed provides full-text links when available. The 2020 transcriptome study ^[23], 2021 proteomics study ^[16], and 2017 immune gene study ^[5] are open-access and fully readable. The stroke review ^[2], depression paper ^[24], and early pharmacology studies ^{[8] [22]} are behind paywalls at their respective journals. If you read Russian, the original trial reports in *Zhurnal nevrologii i psikhiatrii* and *Rossiiskii Fiziologicheskii Zhurnal* contain more detail than the English abstracts. If you don't, you're limited to what's been translated or summarized in secondary reviews. This language barrier is part of why Semax has not gained traction in Western neuroscience or neurology. Reviewers cannot assess what they cannot read.

Is Semax FDA-approved or legally available in the United States?

No, Semax is not FDA-approved. It does not appear in the FDA's approved drug products database ^[3], and it is not listed on the FDA's bulk drug substances list for 503A compounding pharmacies ^[25]. However, providers can prescribe it for off-label use under 21 U.S.C. 353a, which allows pharmacy compounding of non-approved substances when a licensed practitioner determines it is medically necessary for an individual patient ^[4]. Semax cannot be marketed or sold as a drug for any specific indication without FDA approval. Companies that sell it as a dietary supplement or make disease claims are violating 21 CFR 201.128, which defines intended use ^[26]. Enforcement is inconsistent, and gray-market peptide vendors continue to operate, but the legal risk is theirs, not yours as a patient. If you want legal, provider-reviewed Semax, you need a prescription filled by a compounding pharmacy. Semax Labs works with licensed compounding pharmacies to fulfill prescriptions reviewed by U.S.-licensed providers, which keeps the process within the 503A compounding exemption. You're not buying a dietary supplement. You're getting a compounded medication under provider supervision. The alternative is research chemical vendors, often overseas, selling Semax as "not for human consumption." That's how people avoid FDA jurisdiction, but it's also how you get unlabeled, untested, potentially contaminated product. If you're going to use Semax, do it the legal, supervised way.

Frequently asked questions

Are there any double-blind, placebo-controlled human trials of Semax?

Not in major English-language journals as of mid-2024. Russian trials exist, some with placebo groups, but methodological detail is limited in English abstracts. No Western regulatory body has accepted the evidence as sufficient for drug approval.

What's the biggest gap in Semax human research?

Western replication. All published human trials are from Russian institutions, mostly single-center, with small samples. We need independently conducted, preregistered trials in non-Russian populations to know if the effects generalize and whether results hold up under tighter methodological scrutiny.

Has Semax been tested in healthy people or only patients?

Most trials enrolled patients with stroke, brain injury, or cognitive impairment. The 2018 fMRI study used healthy volunteers to measure brain network effects. Cognitive enhancement in healthy adults has not been rigorously tested in published controlled trials.

What's the longest duration Semax has been studied in humans?

30 days in published trials. Stroke and TBI trials typically ran 10 to 21 days. We have no long-term safety or efficacy data beyond one month of continuous use. Chronic use effects remain unknown.

Are the Russian trials peer-reviewed?

Yes, they're published in peer-reviewed Russian journals indexed by PubMed. But peer review standards vary by journal, and many Russian neurology journals do not require preregistration, public protocols, or raw data sharing. Methodological transparency is limited.

Why hasn't anyone in the U.S. or Europe tested Semax?

Probably because the peptide is not patentable (it's a short sequence), so there's no commercial incentive to fund a $10-50 million phase III trial. Academic researchers face language and collaboration barriers with Russian institutions. No pharmaceutical company has picked it up.

What outcome measures did the stroke trials use?

National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index, and cognitive subscales. These are standard stroke trial endpoints, so the results are comparable to Western stroke drug trials in structure if not in quality.

Is there any evidence Semax works for ADHD or focus?

No published trials for ADHD exist. The dopaminergic activation seen in animal studies suggests a mechanism, and anecdotal use is common in nootropic communities, but clinical evidence is absent. It's entirely speculative for attention-deficit disorders.

Can I cite Russian Semax studies in a grant or thesis?

Yes, they're peer-reviewed and PubMed-indexed. But acknowledge the limitations: language barriers, limited methodological transparency, and lack of independent replication. Don't overstate the evidence quality or present it as equivalent to Western regulatory-standard data.

What's the best single study to read on Semax?

The 2020 transcriptome study (PMID 32580520) is open-access, methodologically detailed, and representative of the mechanistic evidence base. For clinical outcomes, the 2018 stroke review (PMID 29798983) summarizes the human data, though it's in Russian with an English abstract.

Does Semax have FDA orphan drug or breakthrough status?

No. It has no FDA designation of any kind. It is not in clinical trials registered with ClinicalTrials.gov as of mid-2024. It has no investigational new drug (IND) application on file with the FDA.

Are there any ongoing Semax trials I can join?

None listed on ClinicalTrials.gov as of July 2024. Russian trials may be ongoing but are not publicly registered on Western trial registries. If you're looking for a trial, there are no publicly accessible enrollment opportunities in the U.S. or Europe.

What's the difference between Semax and N-acetyl Semax amidate in human studies?

Almost all human trials used standard Semax (Met-Glu-His-Phe-Pro-Gly-Pro). N-acetyl Semax amidate is a synthetic analog with longer half-life, but published human data is limited to a few small trials. For a detailed comparison, see semax vs n-acetyl semax amidate.

Is Semax effective if taken orally?

No published human trials used oral Semax. The peptide is degraded by gastric enzymes, which destroys its structure before absorption. All human studies used intranasal or intravenous routes. Semax injection is another option, but intranasal is the standard and most-studied route.

Sources

1. Journal of the American Academy of Orthopaedic Surgeons, 2026 (PMID 41490200): Review discusses therapeutic peptides in orthopedics and mentions Semax as a neuroprotective candidate under investigation for neurotrauma.
2. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018 (PMID 29798983): Clinical review summarized results from multiple Russian trials involving patients at different stages of ischemic stroke, reporting statistically significant improvements in neurological function.
3. FDA Drugs@FDA database: Semax does not appear in the FDA's database of approved drug products.
4. 21 U.S.C. 353a, pharmacy compounding statute: Statute allows pharmacy compounding of non-approved substances when a licensed practitioner determines it is medically necessary for an individual patient.
5. Molecular Genetics and Genomics, 2017 (PMID 28255762): Study found that Semax regulates expression of immune response genes during ischemic brain injury in rats, correlating with reduced inflammation markers.
6. BMC Genomics, 2014 (PMID 24661604): Genome-wide transcriptional analysis showed that Semax affects genes related to immune and vascular systems during focal ischemia in rats.
7. Biomedicines, 2024 (PMID 39767736): Study showed that ACTH-like peptides, including Semax, compensated for gene expression disruptions caused by ischemia in rat brain regions.
8. Neurochemical Research, 2005 (PMID 16362768): Study found that Semax activated dopaminergic and serotonergic brain systems in rodents.
9. Bulletin of Experimental Biology and Medicine, 2018 (PMID 30225715): fMRI study examined Semax's effects on the default mode network of the brain in healthy human volunteers, showing altered connectivity compared to placebo.
10. Acta Naturae, 2025 (PMID 41479572): Study showed that Semax and its derivatives corrected pathological impairments in a rat model of Alzheimer's disease.
11. ACS Chemical Neuroscience, 2022 (PMID 35080861): Study found that Semax affected copper-induced beta-amyloid aggregation and amyloid formation in artificial membrane models.
12. British Journal of Pharmacology, 2025 (PMID 40692165): Study found that Semax targeted the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
13. Doklady Biological Sciences, 2020 (PMID 32342318): Functional connectomic study used graph theory and machine learning to analyze Semax's effects on brain networks in rodents.
14. Current Pharmaceutical Design, 2018 (PMID 28875850): Review discussed the pharmacological aspects of neuro-immune interactions involving Semax but noted the limited Western clinical data.
15. Cellular and Molecular Neurobiology, 2010 (PMID 19633950): Study showed that Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.
16. International Journal of Molecular Sciences, 2021 (PMID 34201112): Brain protein expression profile study confirmed the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion.
17. Rossiiskii Fiziologicheskii Zhurnal, 2010 (PMID 21268834): Study compared different routes of administration (intranasal, subcutaneous, intraperitoneal) in rats and found that intranasal dosing produced nootropic and analgesic effects at lower doses than parenteral routes.
18. Frontiers in Aging, 2026 (PMID 42021992): Review on therapeutic peptides in aging mentioned Semax as a candidate neuroprotective agent.
19. Neuropeptides, 2025 (PMID 41004910): Review on bioactive peptides in neurodegenerative diseases referenced Semax's mechanism but relied entirely on Russian preclinical and clinical sources.
20. Neuropeptides, 2021 (PMID 33418449): Study found that Semax attenuated behavioral and neurochemical alterations following early-life fluvoxamine exposure in white rats without causing toxicity.
21. Chemical Biology & Drug Design, 2023 (PMID 36828803): Study found direct and delayed effects of synthetic corticotropins on the GABA-receptor system.
22. Journal of Neurochemistry, 2006 (PMID 16635254): Study showed that Semax binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.
23. Genes, 2020 (PMID 32580520): Study found that Semax (the ACTH(4-7)PGP peptide) had protective properties at the transcriptome level following cerebral ischemia-reperfusion in rats.
24. CNS Spectrums, 2008 (PMID 18204410): Paper discussed the therapeutic possibility of Semax for depression, citing a small open-label trial in patients with major depressive disorder.
25. FDA bulk drug substances used in compounding under section 503A: Semax is not listed on the FDA's bulk drug substances list for 503A compounding pharmacies.
26. 21 CFR 201.128, meaning of intended uses: Regulation defines intended use for determining whether a substance is marketed as a drug.